| Long noncoding RNA CBR3 antisense RNA 1 promotes the aggressive phenotypes of nonsmallcell lung cancer by sponging microRNA5093p and competitively upregulating HDAC9 expression. | Long noncoding RNA CBR3 antisense RNA 1 promotes the aggressive phenotypes of non‑small‑cell lung cancer by sponging microRNA‑509‑3p and competitively upregulating HDAC9 expression.
Guan Y, Yang J, Liu X, Chu L., Free PMC Article | 07/10/2021 |
| patients with advanced stage retinoblastoma had higher levels of PlncRNA-1 expression than patients with early stage retinoblastoma. There was an inverse correlation between PlncRNA-1 expression and CBR3 expression in retinoblastoma tissues, and PlncRNA-1 negatively regulated mRNA and protein expressions of CBR3. | PlncRNA-1 is overexpressed in retinoblastoma and regulates retinoblastoma cell proliferation and motility through modulating CBR3.
Wang S, Liu J, Yang Y, Hao F, Zhang L. | 08/3/2019 |
| CBR3 730G>A is significantly associated with recurrence- free survival in patients who received intravesical chemotherapy with pirarubicin after complete transurethral resection. | NOS3 895G>T and CBR3 730G>A Are Associated with Recurrence Risk in Non-Muscle-Invasive Bladder Cancer with Intravesical Instillations of THP.
Zhou Q, Ding W, Weng Y, Ding G, Xia G, Xu J, Xu K, Ding Q. | 12/22/2018 |
| No significant correlation between cardiotoxicity and SNPs within the CBR pathway. Further investigation into CBR SNPs in a larger adult sample is needed. | Risk factors for anthracycline-associated cardiotoxicity.
Reinbolt RE, Patel R, Pan X, Timmers CD, Pilarski R, Shapiro CL, Lustberg MB., Free PMC Article | 11/19/2016 |
| association of SNPs in ABCB1 and CBR3 with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines. | Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines.
Hertz DL, Caram MV, Kidwell KM, Thibert JN, Gersch C, Seewald NJ, Smerage J, Rubenfire M, Henry NL, Cooney KA, Leja M, Griggs JJ, Rae JM., Free PMC Article | 09/24/2016 |
| Variants of CBR3 and GSTP1 enzymes may be associated with changes in short-term functional cardiac parameters. | The relationship between changes in functional cardiac parameters following anthracycline therapy and carbonyl reductase 3 and glutathione S transferase Pi polymorphisms.
Volkan-Salanci B, Aksoy H, Kiratli PÖ, Tülümen E, Güler N, Öksüzoglu B, Tokgözoğlu L, Erbaş B, Alikaşifoğlu M. | 05/11/2013 |
| genetic polymorphism in the CBR3 gene conferred risk of type 2 diabetes and insulin resistance in Chinese. The association was probably mediated through modulation of adipogenesis. | Genetic variation in the carbonyl reductase 3 gene confers risk of type 2 diabetes and insulin resistance: a potential regulator of adipogenesis.
Chang YC, Liu PH, Tsai YC, Chiu YF, Shih SR, Ho LT, Lee WJ, Lu CH, Quertermous T, Curb JD, Lee WJ, Lee PC, He YH, Yeh JI, Hwang JJ, Tsai SH, Chuang LM. | 09/29/2012 |
| CBR3 polymorphisms contribute to increased cardiomyopathy risk associated with anthracycline treatment of childhood cancer. | Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group.
Blanco JG, Sun CL, Landier W, Chen L, Esparza-Duran D, Leisenring W, Mays A, Friedman DL, Ginsberg JP, Hudson MM, Neglia JP, Oeffinger KC, Ritchey AK, Villaluna D, Relling MV, Bhatia S., Free PMC Article | 06/30/2012 |
| CBR3 is a novel target gene of inflammatory stimuli; elucidation of its detailed role in inflammation deserves further investigation. | Expression of human carbonyl reductase 3 (CBR3; SDR21C2) is inducible by pro-inflammatory stimuli.
Malátková P, Ebert B, Wsól V, Maser E. | 05/26/2012 |
| A protein encoded by this locus was found to be differentially expressed in postmortem brains from patients with atypical frontotemporal lobar degeneration. | Proteomic analysis identifies dysfunction in cellular transport, energy, and protein metabolism in different brain regions of atypical frontotemporal lobar degeneration.
Martins-de-Souza D, Guest PC, Mann DM, Roeber S, Rahmoune H, Bauder C, Kretzschmar H, Volk B, Baborie A, Bahn S. | 04/26/2012 |
| Computational searches identify a conserved antioxidant response element(ARE) in the distal carbonyl reductase 3 (CBR3) promoter region. | A conserved antioxidant response element (ARE) in the promoter of human carbonyl reductase 3 (CBR3) mediates induction by the master redox switch Nrf2.
Cheng Q, Kalabus JL, Zhang J, Blanco JG., Free PMC Article | 01/21/2012 |
| The CBR3 distal promoter contains an activating cis-regulatory element that is responsive to Trichostatin A (TSA) treatment according to promoter reporter assays in HEK 293 cells. | Functional analysis and identification of cis-regulatory elements of human chromosome 21 gene promoters.
Warnatz HJ, Querfurth R, Guerasimova A, Cheng X, Haas SA, Hufton AL, Manke T, Vanhecke D, Nietfeld W, Vingron M, Janitz M, Lehrach H, Yaspo ML., Free PMC Article | 09/14/2011 |
| a physiological role of CBR1, but not for CBR3, in S-nitrosoglutathione reduction and thus ultimately in regulation of NO signaling | Studies on reduction of S-nitrosoglutathione by human carbonyl reductases 1 and 3.
Staab CA, Hartmanová T, El-Hawari Y, Ebert B, Kisiela M, Wsol V, Martin HJ, Maser E. | 08/27/2011 |
| CBR3 is regulated via NRF2-dependent signaling pathways, a finding and plays an important role in the cellular response to oxidative stress. | Regulation of human carbonyl reductase 3 (CBR3; SDR21C2) expression by Nrf2 in cultured cancer cells.
Ebert B, Kisiela M, Malátková P, El-Hawari Y, Maser E. | 01/29/2011 |
| Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator) | Polymorphisms in innate immunity genes and lung cancer risk in Xuanwei, China.
Shen M, Vermeulen R, Rajaraman P, Menashe I, He X, Chapman RS, Yeager M, Thomas G, Burdett L, Hutchinson A, Yuenger J, Chanock S, Lan Q., Free PMC Article | 04/7/2010 |
| analysis of the structural basis for substrate specificity in human monomeric carbonyl reductases CBR3 | Structural basis for substrate specificity in human monomeric carbonyl reductases.
Pilka ES, Niesen FH, Lee WH, El-Hawari Y, Dunford JE, Kochan G, Wsol V, Martin HJ, Maser E, Oppermann U., Free PMC Article | 03/15/2010 |
| identified the promoter of human CBR3. Liver samples from black donors showed higher relative CBR3 mRNA levels than samples from whites | Identification of the promoter of human carbonyl reductase 3 (CBR3) and impact of common promoter polymorphisms on hepatic CBR3 mRNA expression.
Zhang J, Blanco JG., Free PMC Article | 01/21/2010 |
| CBR3 polymorphisms have no significant influence on the pharmacokinetics of doxorubicin in Asian breast cancer patients. | CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients.
Lal S, Sandanaraj E, Wong ZW, Ang PC, Wong NS, Lee EJ, Chowbay B, Lal S, Sandanaraj E, Wong ZW, Ang PC, Wong NS, Lee EJ, Chowbay B., Free PMC Articles: PMC11160041, PMC11160041 | 01/21/2010 |
| Polymorphisms in CBR3 may explain interindividual and interethnic variability of doxorubicin pharmacokinetics and pharmacodynamics. | Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity.
Fan L, Goh BC, Wong CI, Sukri N, Lim SE, Tan SH, Guo JY, Lim R, Yap HL, Khoo YM, Iau P, Lee HS, Lee SC, Fan L, Goh BC, Wong CI, Sukri N, Lim SE, Tan SH, Guo JY, Lim R, Yap HL, Khoo YM, Iau P, Lee HS, Lee SC. | 01/21/2010 |
| Observational study of gene-disease association. (HuGE Navigator) | See all PubMed (4) articlesA large-scale candidate gene association study of age at menarche and age at natural menopause.
He C, Kraft P, Chasman DI, Buring JE, Chen C, Hankinson SE, Paré G, Chanock S, Ridker PM, Hunter DJ. Genetic susceptibility to distinct bladder cancer subphenotypes.
Guey LT, García-Closas M, Murta-Nascimento C, Lloreta J, Palencia L, Kogevinas M, Rothman N, Vellalta G, Calle ML, Marenne G, Tardón A, Carrato A, García-Closas R, Serra C, Silverman DT, Chanock S, Real FX, Malats N, EPICURO/Spanish Bladder Cancer Study investigators. PTEN identified as important risk factor of chronic obstructive pulmonary disease.
Hosgood HD 3rd, Menashe I, He X, Chanock S, Lan Q. Pathway-based evaluation of 380 candidate genes and lung cancer susceptibility suggests the importance of the cell cycle pathway.
Hosgood HD 3rd, Menashe I, Shen M, Yeager M, Yuenger J, Rajaraman P, He X, Chatterjee N, Caporaso NE, Zhu Y, Chanock SJ, Zheng T, Lan Q. | 09/24/2008 |
| These results suggested that hCBR3 and hCBR1 play distinct physiological roles. | Different functions between human monomeric carbonyl reductase 3 and carbonyl reductase 1.
Miura T, Nishinaka T, Terada T. | 01/21/2010 |
| There was a trend toward an association between the CBR3 V244M polymorphism and the risk of CHf | Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer.
Blanco JG, Leisenring WM, Gonzalez-Covarrubias VM, Kawashima TI, Davies SM, Relling MV, Robison LL, Sklar CA, Stovall M, Bhatia S, Blanco JG, Leisenring WM, Gonzalez-Covarrubias VM, Kawashima TI, Davies SM, Relling MV, Robison LL, Sklar CA, Stovall M, Bhatia S. | 01/21/2010 |
| Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) | See all PubMed (4) articlesNitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial.
Choi JY, Barlow WE, Albain KS, Hong CC, Blanco JG, Livingston RB, Davis W, Rae JM, Yeh IT, Hutchins LF, Ravdin PM, Martino S, Lyss AP, Osborne CK, Abeloff MD, Hayes DF, Ambrosone CB. CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients.
Lal S, Sandanaraj E, Wong ZW, Ang PC, Wong NS, Lee EJ, Chowbay B, Lal S, Sandanaraj E, Wong ZW, Ang PC, Wong NS, Lee EJ, Chowbay B. Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity.
Fan L, Goh BC, Wong CI, Sukri N, Lim SE, Tan SH, Guo JY, Lim R, Yap HL, Khoo YM, Iau P, Lee HS, Lee SC, Fan L, Goh BC, Wong CI, Sukri N, Lim SE, Tan SH, Guo JY, Lim R, Yap HL, Khoo YM, Iau P, Lee HS, Lee SC. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer.
Blanco JG, Leisenring WM, Gonzalez-Covarrubias VM, Kawashima TI, Davies SM, Relling MV, Robison LL, Sklar CA, Stovall M, Bhatia S, Blanco JG, Leisenring WM, Gonzalez-Covarrubias VM, Kawashima TI, Davies SM, Relling MV, Robison LL, Sklar CA, Stovall M, Bhatia S. | 05/14/2008 |
| The common carbonyl reductase 3 (CBR3)valine244methionine polymorphism encodes for CBR3 isoforms with distinctive enzymatic properties, as revealed in DNA variation panels from 10 ethnic groups. | Functional significance of a natural allelic variant of human carbonyl reductase 3 (CBR3).
Lakhman SS, Ghosh D, Blanco JG. | 01/21/2010 |
| Decreased Carbonyl Reductase expression in epithelial ovarian cancer is associated with RLN metastasis and poor survival | Carbonyl reductase as a significant predictor of survival and lymph node metastasis in epithelial ovarian cancer.
Umemoto M, Yokoyama Y, Sato S, Tsuchida S, Al-Mulla F, Saito Y., Free PMC Article | 12/30/2004 |